

04/18/2008

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10599110
Filing Date	
First Named Inventor	Kay Brickmann
Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	133087.11801(101398-1PUS)

U.S. PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/CC/	1	1604981	EP		2005-12-14	ONO PHARMACEUTICAL CO., INC.		<input type="checkbox"/>
/CC/	2	04/81005	WO		2004-09-23	NEUROCRINE BIOSCIENCES, INC.		<input type="checkbox"/>
/CC/	3	03/31410	WO		2003-04-17	NEUROCRINE BIOSCIENCES, INC.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10599110
Filing Date		
First Named Inventor	Kay Brickmann	
Art Unit	1614	
Examiner Name	Not yet assigned	
Attorney Docket Number	133087.11801(101398-1PUS)	

/CC/	4	03/28641	WO		2003-04-10	TAISHO PHARMACEUTICAL CO., LTD.		<input type="checkbox"/>
/CC/	5	04/87669	WO		2004-10-14	TAISHO PHARMACEUTICAL CO., LTD.		<input type="checkbox"/>
	6							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/CC/	1	Notice of Co-Pending Applications.	<input type="checkbox"/>
	2		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Celia Chang/	Date Considered	02/25/2010
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.